MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion

Vaccine Evaluation Panel Meeting on March 4 A Japanese health ministry panel on March 4 agreed that there is no problem with the inclusion of MSD’s nine-valent HPV vaccine Silgard 9 into the national immunization program (NIP) from the standpoint...read more